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Introduction
Hepatitis A is an indolent disease with a varying clinical
spectrum and consequences. Little is known about the
immune response to hepatitis A virus (HAV) vaccination,
in children with Juvenile Idiopathic Arthritis (JIA).
Objectives
To assess the sero-protective efficacy and safety of
immunization against hepatitis A in JIA patients on
immunosuppressive treatment, not previously exposed
to HAV, and compare this to healthy controls.
Methods
Matched case control study including patients with JIA
and controls. All subjects received two doses of inacti-
vated anti-HAV at 0 and 6 months. Seroconversion rates
and anti-HAV IgG antibodies were assessed 4 weeks after
the first dose and at 4 and 52 weeks after the last dose.
The protective level of IgG antibodies against HAV was
set as antiHAV>20mIu/ml. Children were monitored for
localized or systemic adverse events for three days and
for disease relapse for three months post vaccination.
Exclusion criteria were infection or disease flare conco-
mitant or up to four weeks prior to immunization, recent
use of steroids (<3m), known liver disease or immunode-
ficiency, and serum testing positive for HAV infection.
Data were analyzed using SPSS 17.0.
Results
Eighty-three patients with a mean age of 6.4 years com-
pleted the study; 21 had polyarticular JIA, 7 had psoria-
tic JIA, 16 had ERA and 39 had oligoarticular JIA.
Twenty-one patients received anti-TNFa, 35 received
methotrexate and 27 received both. The control group
consisted of 76 healthy individuals (mean age 5.2 years).
At four weeks after primary vaccination 48% of patients
and 65% (P<0.01) of the controls attained seroprotection.
Ninety-four percent of the patients and 99% (P=0.07) of
the controls seroconverted four weeks after the second
dose. Seroconversion rate was 91.5% for the patient
group and 97% for the controls at 52 weeks post the sec-
ond dose. Mean IgG concentration at 4 weeks was
45mIU/ml in the patient and 89mIU/ml in the control
group (P=0.04) while it reached 118mIU/ml and 213
mIU/ml after the second dose respectively (P=0.03).
Subgroup analysis showed patients on biologics had
better seroconversion rates compared to children on
MTX or children on biologics+MTX. Vaccines were well
tolerated. Mild adverse events were noticed in 7 patients
and 8 controls. None of the patients developed a flare.
Conclusion
Two doses of HAV vaccine are safe and effective in the
majority of children with JIA, whereas a single dose
seems inefficient. Systemic illness should not preclude
from completion of the vaccination schedule. Serocon-
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